Brought to you by 
Pfizer & Neurogen to develop sleep disorder drugs
12 Nov 2002
Executive Summary
Neurogen Corp. and Pfizer Inc. will collaborate to develop innovative drugs for treating sleep disorders. This deal, the second between these companies, is potentially worth $20 million or more to Neurogen.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer & Neurogen to develop sleep disorder drugs
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice